我要投票 达因盖笛欣在补钙行业中的票数:589
· 外 推 电 报 ·
2025-12-03 09:13:32 星期三

【达因盖笛欣是哪个国家的品牌?】

达因盖笛欣是什么牌子?「达因盖笛欣」是 山东达因海洋生物制药股份有限公司 旗下著名品牌。该品牌发源于山东,由创始人张璨在1994-10-27期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力达因盖笛欣品牌出海!将品牌入驻外推网,定制达因盖笛欣品牌推广信息,可以显著提高达因盖笛欣产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

山东达因海洋生物制药股份有限公司成立于1994年10月,是一家高科技制药企业,注册地在山东省荣成市。公司名称原为威海达因海洋生物制药有限公司,2000年10月,因公司发展的需要,整体改制为股份公司,同时更名为山东达因海洋生物制药股份有限公司,目前公司注册资金6000万元,公司总资产达20000多万元。下设全资子公司北京达因康健医药有限责任公司。

公司主要股东为山大华特科技股份有限公司、荣成市公有资产经营有限公司和中国医学科学院医药生物技术研究所等,其中山大华特科技股份有限公司是山东大学控股的山东省高校唯一上市公司。公司的主营业务为生产销售中西药制剂及原料药、海洋生物药品,产品主要以儿童保健和治疗领域为主,产品是:伊可新(维生素AD胶囊型)、盖笛欣(复方碳酸钙泡腾颗粒剂)、伊甘欣(甘草锌颗粒剂),同时涉及内分泌、心血管、消化系统及抗感染等领域,剂型有软胶囊、硬胶囊、片剂、颗粒剂和原料药。公司管理总部设在北京,生产基地位于山东荣成,并在全国设有20多个销售分支机构。

公司现有生产基地(荣成)厂区占地面积53亩,建筑面积约2万平方米,拥有软胶囊、固体制剂等多条现代化生产线及原料药车间,所有生产线全部通过了国家GMP认证,目前年可生产软胶囊6亿粒,颗粒剂1亿袋。另外,公司已经开工建设的新厂区占地近200亩,预计2009年建成投产后将具备软胶囊12亿粒、颗粒剂10亿袋、口服液5亿支的生产能力。

公司以“使千千万万中国儿童健康强壮”为己任,致力于“成为儿童保健和治疗领域的领军企业”的宏伟战略目标,自成立以来一直以管理规范、业绩优良、成长性好在业内赢得广泛好评。1997年被山东省科委评为高新技术企业,2003年被威海市评为百佳诚信企业,2004年公司产品“伊可新”商标被评为山东省著名商标,并被评为山东省名牌产品,2008年3月“伊可新”商标又被国家工商总局评为中国“驰名保护”。公司销售收入连年增长,年平均增长率均保持在50%以上。根据国家发展和改革委员会的《中国医药统计年报》2005年公司的销售收入、利润总额进入全国化学制药工业前200强的行列。主要产品伊可新已连续九年保持同类产品市场占有率第一。

公司现有员工五百余人,是一个具有优秀的专业化素质以及强烈“责任心、进取心和事业心”和高度执行力的朝气蓬勃的团队。公司秉承“认真做事,诚信做人”的价值观,本着“勤奋、务实、高效、创新”的工作准则,努力为员工创造良好的工作氛围,搭建公司百年发展平台,保证公司稳健经营和持续发展,服务社会,贡献大众。

英文翻译:Shandong dyne marine biopharmaceutical Co., Ltd. was founded in October 1994. It is a high-tech pharmaceutical enterprise, registered in Rongcheng City, Shandong Province. The name of the company was originally Weihai dyne marine bio Pharmaceutical Co., Ltd. in October 2000, due to the needs of the company's development, the company was restructured as a joint-stock company as a whole, and was renamed as Shandong dyne marine bio Pharmaceutical Co., Ltd. at present, the registered capital of the company is 60 million yuan, and the total assets of the company are more than 200 million yuan. It has a wholly-owned subsidiary Beijing dyne Health Medicine Co., Ltd. The main shareholders of the company are Shanda Huate Technology Co., Ltd., Rongcheng City Public Assets Management Co., Ltd. and Institute of pharmaceutical biotechnology, Chinese Academy of Medical Sciences, etc., among which Shanda Huate Technology Co., Ltd. is the only listed company in Shandong Universities controlled by Shandong University. The main business of the company is to produce and sell Chinese and Western medicine preparations, APIs and marine biological drugs. The products are mainly in the field of children's health care and treatment. The products are: ikosin (vitamin AD capsule type), gedixin (compound calcium carbonate effervescent granules), iganxin (glycyrrhizin zinc granules). Meanwhile, they are involved in the fields of endocrine, cardiovascular, digestive system and anti infection Type A includes soft capsule, hard capsule, tablet, granule and API. The company's management headquarters is located in Beijing, the production base is located in Rongcheng, Shandong Province, and has more than 20 sales branches across the country. The company's existing production base (Rongcheng) covers an area of 53 mu, with a building area of about 20000 square meters. It has a number of modern production lines and API workshops, including soft capsules and solid preparations. All production lines have passed the national GMP certification. At present, it can produce 600 million soft capsules and 100 million bags of granules annually. In addition, the company has started the construction of a new plant area of nearly 200 mu, which is expected to have a production capacity of 1.2 billion soft capsules, 1 billion bags of granules and 500 million pieces of oral liquid when it is completed and put into operation in 2009. The company takes "making tens of millions of Chinese children healthy and strong" as its own responsibility, and is committed to the grand strategic goal of "becoming a leading enterprise in the field of children's health care and treatment". Since its establishment, it has been widely praised in the industry for its standardized management, excellent performance and good growth. In 1997, it was rated as a high-tech enterprise by Shandong Provincial Science and Technology Commission; in 2003, it was rated as one of the top 100 integrity enterprises by Weihai City; in 2004, the company's product "ikxin" trademark was rated as a famous trademark in Shandong Province, and it was rated as a famous brand product in Shandong Province; in March 2008, the "ikxin" trademark was rated as China's "well-known protection" by the State Administration of industry and commerce. The company's sales revenue has been increasing year by year, with an average annual growth rate of more than 50%. According to the annual report of China Pharmaceutical statistics issued by the national development and Reform Commission, the company's total sales revenue and profit in 2005 ranked among the top 200 in the national chemical pharmaceutical industry. The market share of its main products, icoxin, has been the first for nine consecutive years. The company has more than 500 employees. It is a vigorous team with excellent professional quality, strong sense of responsibility, enterprise and high execution. The company adheres to the value of "doing things conscientiously, being a man with integrity", and the working principle of "diligence, pragmatism, efficiency and innovation", strives to create a good working atmosphere for employees, build a century long development platform of the company, ensure the stable operation and sustainable development of the company, serve the society and contribute to the public.

本文链接: https://www.waitui.com/brand/f98a48d31.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

华泰证券2026年度交运展望:聚焦供需改善和成长个股

36氪获悉,华泰证券研报称,交运三条投资主线:航空、油运、α个股。展望2026年,我们推荐三条主线:1.航空:供给进一步放缓+需求边际改善,有望从25年的客座率提升,切换到26年的票价提升,叠加油/汇走势利好,盈利具备高弹性。2.油运:受益于OPEC+增产、长航距国家原油出口量增加与地缘扰动,油运运价中枢有望显著抬升。3.α个股:估值具备吸引力的行业龙头、细分赛道空间广阔的个股、受益于配置盘增加的高股息个股。

2小时前

“两重”项目牵引,扩大有效投资有力度

扩大有效投资,冲刺全年经济增长目标。临近年底,各地一批“两重”建设项目不断刷新“进度条”。同时,各类投资向“新”集聚,我国投资结构总体呈持续优化态势。从今年前10个月来看,扣除价格因素,固定资产投资保持小幅增长,投资的实物工作量仍在增加。多位专家表示,随着新型政策性金融工具加快投放等,预计很快会形成实物工作量,加上其他各项促投资政策陆续落地,将有效撬动大量投资,今年全年投资有望实现温和增长。(上证报)

2小时前

央行多重政策工具护航年末流动性

12月2日,中国人民银行(以下简称“央行”)披露2025年11月中央银行各项工具流动性投放情况。数据显示,11月公开市场国债买卖净投放500亿元,抵押补充贷款(PSL)净投放254亿元,其他结构性货币政策工具净投放1150亿元,中期借贷便利(MLF)净投放1000亿元。尽管同期7天期逆回购操作为净回笼,但通过加大中长期流动性工具的运用与搭配,央行在整体上依然实现了资金面的净投放。(经济参考报)

2小时前

中金:布局年末政策窗口期

36氪获悉,中金认为,中美重磅会议落地前,无论是美国宽松预期继续发酵,还是中国增量政策预期抬升,都可能支持风险资产表现。我们建议会议前维持超配中国股票,风格更均衡,会议后根据政策情况选择风格板块。目前成长风格已经经历一轮明显回调,可能存在反弹机会;周期价值风格估值相对较低,存在补涨空间;进入12月下旬,红利资产也可能凸显防御价值。整体而言,沪深300指数动态市盈率12倍,接近历史均值,估值与此前牛市高点比还有充分扩张空间,我们认为中国股票牛市尚未结束。

2小时前

芝商所称美国证交会已批准其设立国债和回购交易清算所

芝商所表示,美国证券交易委员会已批准注册一家新的清算机构,帮助市场遵守证交会关于国债和回购交易的新规定。芝商所在声明中表示,芝商所证券清算公司预计到2026年年中投入运营将,将帮助市场参与者遵守证交会关于美国国债和回购交易的清算规定,这些规定分别将于2026年12月31日和2027年6月30日生效。固定收益清算公司(FICC)是美国证券托管结算公司(DTCC)的附属部门,也是近30万亿美元国债市场中唯一负责清算交易的机构。(新浪财经)

2小时前

本页详细列出关于达因盖笛欣的品牌信息,含品牌所属公司介绍,达因盖笛欣所处行业的品牌地位及优势。
咨询